Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Area of Science:

• Hepatobiliary cancers
• Oncology
• Molecular targeted therapy

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally.
• Sorafenib offers a modest survival benefit for advanced HCC but is the sole approved drug.
• Genomic understanding of HCC has not translated into improved clinical outcomes.

Purpose of the Study:

• To discuss the current challenges in hepatocellular carcinoma drug development.
• To analyze the reasons behind recent clinical trial failures in HCC therapies.
• To propose a shift towards a personalized treatment paradigm for HCC.

Main Methods:

• Review of recent phase III clinical trial outcomes for novel molecularly targeted therapies in HCC.
• Analysis of potential contributing factors to trial failures, including heterogeneity and biomarker absence.
• Discussion of strategies to improve future HCC drug development.

Main Results:

• Multiple first and second-line phase III trials of novel molecularly targeted therapies for HCC have failed.
• Clinical and molecular heterogeneity, suboptimal trial design, and lack of predictive biomarkers are implicated in these failures.
• Current drug development strategies for HCC require re-evaluation.

Conclusions:

• Recent failures underscore a crisis in HCC drug development, necessitating a change in investigational approaches.
• Learning from past trial failures is crucial for developing more effective, personalized treatment strategies for HCC patients.
• A paradigm shift towards personalized medicine is essential for advancing HCC therapy.